Format
Sort by

Send to

Choose Destination

Selected items

Items: 20

1.

Health benefits of Kung Fu: a systematic review.

Tsang TW, Kohn M, Chow CM, Singh MF.

J Sports Sci. 2008 Oct;26(12):1249-67. doi: 10.1080/02640410802155146. Review.

PMID:
18803067
2.

Gee Fu: a sequence version and web-services database tool for genomic assembly, genome feature and NGS data.

Ramirez-Gonzalez R, Caccamo M, MacLean D.

Bioinformatics. 2011 Oct 1;27(19):2754-5. doi: 10.1093/bioinformatics/btr442. Epub 2011 Jul 29.

3.

Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study.

Presant CA, Jacobson J, Wolf W, Waluch V, Weitz IC, Macdonald JS; Southwest Oncology Group.

Invest New Drugs. 2002 Nov;20(4):369-76.

PMID:
12448653
5.

Advanced gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion of 5-FU, MMC and peroral administration of 5-FU: a case report.

Aoyagi K, Koufuji K, Yano S, Murakami N, Terasaki Y, Yamasaki Y, Takeda J, Shirouzu K.

Kurume Med J. 2000;47(4):325-7.

7.

Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.

Antón A, Aranda E, Carrato A, Marcuello E, Massutti B, Cervantes A, Abad A, Sastre J, Fenández-Martos C, Gallén M, Díaz-Rubio E, Huarte L, Balcells M; TTD cooperative group.

Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):639-43.

PMID:
14671682
8.

Destruction of both extensive local recurrent and primary breast cancer with topical aqueous 5-FU: a clinical observation.

Zweig JI, Kabakow B.

Cancer Treat Rep. 1986 Jul;70(7):936-7. No abstract available.

PMID:
3719590
9.
10.

Topical 5-FU--a new approach to skin cancer.

Williams AC.

Ann Surg. 1971 Jun;173(6):864-71. No abstract available.

11.

Pharmacology of WEB 1881-FU, a central cholinergic agent, which enhances cognition and cerebral metabolism.

Kuhn FJ, Schingnitz G, Lehr E, Montagna E, Hinzen HD, Giachetti A.

Arch Int Pharmacodyn Ther. 1988 Mar-Apr;292:13-34.

PMID:
3395164
12.
13.

Skin reaction to systemic 5-FU-a therapeutic bonus.

Omura EF.

N Engl J Med. 1977 Oct 27;297(17):946. No abstract available.

PMID:
904673
14.

[Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report].

Nakanishi K, Ueno Y, Nakamura N, Yoshikawa H, Takeuchi T, Tanihata H, Masuda M, Terada M, Satoh M, Okamoto E.

Gan To Kagaku Ryoho. 1999 Feb;26(3):353-6. Japanese.

PMID:
10065099
15.

Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist.

Kitamura Y, Kaneda T, Nomura Y.

Jpn J Pharmacol. 1991 Jan;55(1):177-80.

16.

Nasal cartilage necrosis following high-dose 5-FU: a case report.

Ashford RF, Mughal T, Goold MA, Smith BJ, Phillips RH, MacKay IS.

Cancer Treat Rep. 1982 Oct;66(10):1884. No abstract available.

PMID:
7127331
17.

Use of high-dose oral methotrexate sequenced at 24 hours with 5-FU: a clinical toxicity study.

Benz C, Silverberg M, Cadman E.

Cancer Treat Rep. 1983 Mar;67(3):297-9.

PMID:
6831477
18.

Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study.

Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK.

Cancer. 1976 Jul;38(1):1-7.

19.

Thymidine and 5-FU: a Phase II pilot study in colorectal and breast carcinomas.

Presant CA, Multhauf P, Klein L, Chan C, Chang FF, Hum G, Joseph R, Opfell R, Lemkin S, Shiftan T, Plotkin D.

Cancer Treat Rep. 1983 Jul-Aug;67(7-8):735-6. No abstract available.

PMID:
6871891
20.

[Postoperative abdominal lymph node recurrence of intrathoracic esophageal cancer with a long-term complete response to radiation and split CF therapy (CDDP and 5-FU)--a case report].

Nishino N, Aoki K, Konno H, Maruo Y, Tanaka T, Matsuda I, Kanai T, Baba S.

Gan To Kagaku Ryoho. 1995 Aug;22(9):1249-52. Japanese.

PMID:
7661576
Items per page

Supplemental Content

Write to the Help Desk